Myelodysplastic Syndromes
📧 Sign up to get email alerts when something new happens for Myelodysplastic Syndromes.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-12Clinical Trial Results: Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation [NA]
A completed clinical trial evaluating an electronic mindfulness-based music therapy intervention for patients undergoing allogeneic stem cel…
-
CLINICAL_TRIALS trial_result · 2026-07-06Clinical Trial Results: First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) [Phase 1, Phase 2]
First-in-human study results for SAR443579 in relapsed or refractory acute leukemias and BPDCN across Phase 1/2 cohorts; the study was termi…
-
CLINICAL_TRIALS trial_result · 2026-06-17Clinical Trial Results: A Study of E7820 in People With Bone Marrow (Myeloid) Cancers [Phase 2]
Phase 2 trial results for E7820 in myeloid bone marrow cancers have been completed with posted results.
-
EMA approval · 2026-06-12EMA Authorised: Azacitidine Mylan (azacitidine) — Mylan Pharmaceuticals Limited
European Medicines Agency authorises Azacitidine Mylan for myelodysplastic syndromes and various leukemias, confirming market authorization …
-
CLINICAL_TRIALS trial_result · 2026-06-08Clinical Trial Results: Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent [Phase 2]
Phase 2 trial evaluating recombinant EphB4-HSA with azacitidine or decitabine in relapsed/refractory MDS, CMML, or AML after hypomethylating…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances [Phase 1, Phase 2]
A Phase I/II clinical trial evaluating CAR.70, engineered IL-15-transduced cord blood-derived natural killer (NK) cells, in combination with…
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors [Phase 1]
A Phase 1 trial evaluating the combination of bortezomib and clofarabine in adults with relapsed solid tumors has been completed. The listed…
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS) [Phase 2]
Phase 2 trial update evaluating tebapivat (AG-946) for anemia in patients with lower-risk myelodysplastic syndromes. The study is currently …
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS
This document notes an expanded access program for Galinpepimut-S (GPS) in patients with acute myeloid leukemia or myelodysplastic syndromes…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression [Phase 1, Phase 2]
AstraZeneca is evaluating AZD3632 as monotherapy or with other anticancer agents in adults with advanced hematologic malignancies associated…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Phase 2 Study Of Imetelstat for Patient With Myelodysplastic/Myeloproliferative Neoplasms [Phase 2]
Phase 2 clinical trial update for imetelstat in patients with myelodysplastic/myeloproliferative neoplasms; the study status is NOT_YET_RECR…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms [Phase 1, Phase 2]
Pacritinib is being studied in Phase 1/2 trials for myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms in adults and…
-
CLINICAL_TRIALS trial_result · 2026-04-23Clinical Trial Update: A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating Bexmarilimab in combination with standard of care for hematologic malignancies is active but not recru…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Research for Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-MDS) in the Treatment of Myelodysplastic Syndrome (MDS) [Phase 1, Phase 2]
A clinical trial update indicates that a Phase 1/Phase 2 study evaluating human umbilical cord mesenchymal stem cells (iSCLife-MDS) for myel…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Study of BGB-11417 in Participants With Myeloid Malignancies [Phase 1, Phase 2]
BeiGene is testing BGB-11417 in Phase 1/2 trials for myeloid malignancies, including acute myeloid leukemia and myelodysplastic syndromes, w…
-
CLINICAL_TRIALS trial_result · 2026-04-23Clinical Trial Update: A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia [Phase 2]
Phase 2 trial update on epigenetic priming in newly diagnosed acute myeloid leukemia; the study is currently active but not recruiting.
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or Myelofibrosis [NA]
A feasibility clinical trial evaluating extracorporeal iron purification as a treatment approach for patients with myelodysplastic syndromes…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Leflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory Myelodysplastic Syndromes [Phase 1, Phase 2]
Ongoing Phase 1/2 clinical trial evaluating leflunomide in combination with decitabine for relapsed or refractory myelodysplastic syndromes.…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome [Phase 2]
A Phase 2 clinical trial evaluating momelotinib in adults with low-risk myelodysplastic syndromes is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia [Phase 2]
A Phase 2 clinical trial is evaluating tranexamic acid in patients with myelodysplastic syndromes and acute myeloid leukemia and is currentl…
-
CLINICAL_TRIALS trial_result · 2026-04-21Clinical Trial Update: Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015 [NA]
This clinical trial update reports on predictive clinical and biological parameters across acute leukemia, myelodysplastic syndromes, and my…
-
CLINICAL_TRIALS trial_result · 2026-04-17Clinical Trial Update: Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL) [Phase 2]
Phase 2 study of fedratinib in myeloproliferative neoplasms, chronic neutrophilic leukemia, and myelodysplastic syndromes; the trial is not …
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics [Phase 1]
First-in-human Phase 1 study of AUR 103 Calcium to evaluate safety, pharmacokinetics, and pharmacodynamics in adults with acute myeloid leuk…
-
CLINICAL_TRIALS research · 2026-04-17Clinical Trial Update: A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemia [Phase 2]
A Phase 2a trial update for HT-6184 in patients with IPSS-R very low/low/intermediate risk myelodysplastic syndromes and anemia, with the st…
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure [Phase 2]
A Phase II clinical trial is evaluating Vibecotamab (XmAb14045) for patients with measurable residual disease-positive acute myeloid leukemi…